Type 2 diabetes Therapies Class Biguanide DPP4 Inhibitors

Type 2 diabetes Therapies Class Biguanide DPP-4 Inhibitors GLP-1 R Agonists SGLT-2 Inhibitors Agent A 1 c BW Hypos Comments $/j Metformin (Glucophage) ↓↓ ↓ No Diarrhea, lower mortality 0. 48 Sitagliptin (Januvia) ↓↓ Stable No Saxagliptin (Onglyza) ↓↓ Stable No Linagliptin (Trajenta) ↓↓ Stable No Liraglutide (Victoza) ↓↓↓ ↓↓ No Exenatide (Byetta) ↓↓↓ ↓↓ No Alpha-Glucosidase Inhibitors Insulin Long-term safety not established 2. 30 2. 25 Injection, long-term safety not established 6. 85 5. 00 No Hypotension, genital mycotic infections, long-term safety not established 2. 62 ↑↑ No Edema, heart failure, fractures, myocardial infarcts ? 2. 85 ↓↓ ↑↑ No Edema, heart failure fractures, bladder cancer? 2. 29 Glyburide (Diabeta) ↓↓ ↑↑ +++ 0. 28 Gliclazide (Diamicron) ↓↓ ↑↑ ++ 0. 56 Glimepiride (Amaryl) ↓↓ ↑↑ ++ 0. 78 Repaglinide (Gluco. Norm) ↓↓ ↑↑ +++ 1. 62 Nateglinide (Starlix) ↓ ↑↑ ++ 1. 95 Acarbose (Gluco. Bay) ↓ ↓ No Gas 0. 96 Human Insulin ↓↓↓ ↑↑ +++++ Injections 1. 77 Analog insulin ↓↓↓ ↑↑ ++++ Injections 1. 95 R 4. 54 L Canagliflozin (Invokana) Dapagliflozin (Forxiga) ↓ ↓ to ↓↓↓ ↓↓ Rosiglitazone (Avandia) ↓↓ Pioglitazone (Actos) Thiazolidinediones Insulin Secretagogues 2. 62